Ken Griffin Bio Techne Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Techne Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 35,100 shares of TECH stock, worth $2.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,100

Previous 43,500 19.31%

Holding current value

$2.37 Million

Previous $3.12 Million 10.01%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$70.96 - $82.35 $67.2 Million - $77.9 Million	946,543 Added 366.96%	1,204,484 $96.3 Million
Q2 2024 Aug 14, 2024	BUY	$62.12 - $84.15 $9.75 Million - $13.2 Million	156,876 Added 155.22%	257,941 $18.5 Million
Q1 2024 May 15, 2024	BUY	$65.98 - $77.09 $6.67 Million - $7.79 Million	101,065 New	101,065 $7.11 Million
Q3 2023 Nov 14, 2023	BUY	$67.52 - $89.42 $13.9 Million - $18.5 Million	206,426 Added 194.55%	312,533 $21.3 Million
Q2 2023 Aug 14, 2023	SELL	$73.76 - $85.98 $32.9 Million - $38.4 Million	-446,457 Reduced 80.8%	106,107 $8.66 Million
Q1 2023 May 15, 2023	BUY	$71.62 - $86.62 $36.6 Million - $44.2 Million	510,677 Added 1219.18%	552,564 $41 Million
Q4 2022 Feb 14, 2023	SELL	$80.67 - $352.29 $6.09 Million - $26.6 Million	-75,545 Reduced 64.33%	41,887 $3.47 Million
Q3 2022 Nov 14, 2022	BUY	$282.54 - $391.85 $31.1 Million - $43.1 Million	109,981 Added 1476.06%	117,432 $33.4 Million
Q2 2022 Aug 15, 2022	SELL	$322.67 - $449.65 $13.8 Million - $19.3 Million	-42,887 Reduced 85.2%	7,451 $2.58 Million
Q1 2022 May 16, 2022	BUY	$353.85 - $487.79 $17.3 Million - $23.9 Million	48,990 Added 3634.27%	50,338 $21.8 Million
Q4 2021 Feb 14, 2022	SELL	$456.15 - $525.06 $9.58 Million - $11 Million	-20,997 Reduced 93.97%	1,348 $697,000
Q3 2021 Nov 15, 2021	BUY	$444.87 - $538.88 $1.11 Million - $1.34 Million	2,485 Added 12.51%	22,345 $10.8 Million
Q2 2021 Aug 16, 2021	BUY	$387.35 - $450.26 $7.29 Million - $8.48 Million	18,833 Added 1833.79%	19,860 $8.94 Million
Q1 2021 May 17, 2021	SELL	$314.62 - $411.0 $5.51 Million - $7.2 Million	-17,509 Reduced 94.46%	1,027 $392,000
Q4 2020 Feb 16, 2021	BUY	$246.9 - $321.87 $2.11 Million - $2.74 Million	8,526 Added 85.17%	18,536 $5.89 Million
Q3 2020 Nov 16, 2020	SELL	$232.22 - $282.96 $10.8 Million - $13.1 Million	-46,436 Reduced 82.27%	10,010 $2.48 Million
Q2 2020 Aug 14, 2020	BUY	$185.43 - $279.56 $8.81 Million - $13.3 Million	47,503 Added 531.18%	56,446 $14.9 Million
Q1 2020 May 15, 2020	SELL	$161.17 - $221.51 $8.15 Million - $11.2 Million	-50,574 Reduced 84.97%	8,943 $1.7 Million
Q4 2019 Feb 14, 2020	BUY	$189.68 - $222.09 $9.88 Million - $11.6 Million	52,075 Added 699.74%	59,517 $13.1 Million
Q3 2019 Nov 14, 2019	SELL	$183.56 - $216.72 $13.3 Million - $15.7 Million	-72,403 Reduced 90.68%	7,442 $1.46 Million
Q2 2019 Aug 14, 2019	SELL	$188.72 - $215.43 $6.47 Million - $7.39 Million	-34,305 Reduced 30.05%	79,845 $16.6 Million
Q1 2019 May 15, 2019	BUY	$136.09 - $200.44 $10 Million - $14.8 Million	73,834 Added 183.14%	114,150 $0
Q4 2018 Feb 14, 2019	BUY	$132.75 - $203.8 $142,440 - $218,677	1,073 Added 2.73%	40,316 $5.83 Million
Q3 2018 Nov 13, 2018	SELL	$147.44 - $204.11 $1.86 Million - $2.57 Million	-12,598 Reduced 24.3%	39,243 $0
Q2 2018 Aug 10, 2018	SELL	$144.9 - $165.58 $2.6 Million - $2.97 Million	-17,950 Reduced 25.72%	51,841 $0
Q1 2018 May 11, 2018	SELL	$131.46 - $151.04 $45.6 Million - $52.4 Million	-346,945 Reduced 83.25%	69,791 $10.5 Million
Q4 2017 Feb 09, 2018	BUY	$121.17 - $134.75 $11.3 Million - $12.6 Million	93,175 Added 28.8%	416,736 $54 Million
Q3 2017 Nov 09, 2017	BUY	$113.59 - $123.78 $36.8 Million - $40.1 Million	323,561	323,561 $39.1 Million

Others Institutions Holding TECH

# of Institutions

603

Shares Held

151M

Call Options Held

195K

Put Options Held

53.2K

View Full List

About BIO-TECHNE Corp

Ticker TECH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,222,600
Market Cap $2.65B
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures bi...

More about TECH

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account